-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Several studies have investigated the relationship between cognitive measures and AD PET pathological markers
Similarly, the relationship between Aβ-PET burden and cognition has been reported in both clinical mixed samples and cognitive accessibility samples.
However, compared with tau, the impact of greater Aβ burden on cognitive performance is often weaker, which may be due to the fact that tau pathology is more closely related to neuronal loss in affected brain regions
Timely and cost-effective clinical markers closely related to Aβ and tau markers may help to greatly reduce the clinical need for PET scanning, and achieve multimodal case identification, as a possible long-term clinical and diagnostic evaluation.
diagnosis
In the sub-samples of MCI and dementia patients, the Favorites in the midtemporal area, the Match in the frontal parietal area, and the Line Orientation (visual spatial skills) in the parietal area were significantly correlated with the Tau-PET signal
The important significance of this study lies in the discovery: BHA measures are significantly related to the in vivo imaging markers of Aβ and regional tau, which can be used to identify patients with suspected AD pathology in clinical practice
BHA measures are clearly related to the in vivo imaging markers of Aβ and regional tau, which can be used to identify patients with suspected AD pathology in clinical practice
Leave a message here